Catalyst Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2004
Net Income	71.41	83.08	39.48	74.98	31.88	-34	-18.41	-18.07	-20.23	-15.51	Upgrade
Depreciation & Amortization	33.14	1.49	0.48	0.89	0.3	0.04	0.05	0.04	0.03	0.03	Upgrade
Share-Based Compensation	14.25	7.91	6.07	6.26	3.83	3.55	2.41	1.84	1.59	0.78	Upgrade
Other Operating Activities	24.8	23.58	14.33	-37.1	-1.39	4.27	2.22	-1.77	0.6	1.76	Upgrade
Operating Cash Flow	143.6	116.05	60.37	45.03	34.61	-26.15	-13.74	-17.96	-18.02	-12.94	Upgrade
Operating Cash Flow Growth	23.74%	92.22%	34.06%	30.11%	-	-	-	-	-	-	Upgrade
Capital Expenditures	-0.23	-0.03	-1.02	-0.01	-0.02	-0.09	0	-0.1	-0.02	-0.06	Upgrade
Acquisitions	-198.29	-10	0	0	0	0	0	0	0	0	Upgrade
Change in Investments	-13.47	19.24	-10	-5	37.24	-14.99	-0	3.65	0.02	-8.68	Upgrade
Other Investing Activities	-81.51	-	-	-	-	-	-	-	-	-	Upgrade
Investing Cash Flow	-293.5	9.21	-11.02	-5.01	37.23	-15.08	-0	3.55	-0.01	-8.74	Upgrade
Share Issuance / Repurchase	2.79	2.66	-7.99	0.76	1.12	0.3	57.35	0.08	37.16	28.56	Upgrade
Other Financing Activities	-13.65	-0.97	-0.15	-0.06	-	-0	-	-0.01	-	-	Upgrade
Financing Cash Flow	-10.86	1.69	-8.14	0.7	1.12	0.29	57.35	0.07	37.16	28.56	Upgrade
Net Cash Flow	-160.76	126.95	41.21	40.73	72.95	-40.94	43.6	-14.34	19.14	6.88	Upgrade
Free Cash Flow	143.37	116.02	59.35	45.02	34.59	-26.24	-13.74	-18.06	-18.04	-13	Upgrade
Free Cash Flow Growth	23.57%	95.48%	31.82%	30.15%	-	-	-	-	-	-	Upgrade
Free Cash Flow Margin	36.00%	54.16%	42.14%	37.81%	33.81%	-5247.91%	-	-	-	-	Upgrade
Free Cash Flow Per Share	1.35	1.12	0.57	0.43	0.34	-0.26	-0.16	-0.22	-0.22	-0.20	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).